Anika to Participate in the 2019 Morgan Stanley Global Healthcare Conference on September 10, 2019

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that Joseph Darling, President and Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat at the 2019 Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019 at 8:35 am ET. The conference is being held at the Grand Hyatt Hotel in New York, NY.

A live audio webcast of the session may be accessed via the “Investor Relations” section of Anika’s website at www.anikatherapeutics.com. An audio archive of the session will also be available on the website.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, viscosupplements which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005775/en/

For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung, 781-457-9000 Chief Financial Officer or For Media Inquiries: Pure Communications, Inc. Sonal Vasudev, 917-523-1418 [e-mail]